Kiso Health

What Kiso Health does

Kiso Health GmbH is an 8-person Berlin-based digital therapeutics company spun out of Charité Universitätsmedizin Berlin. It develops mobile applications for people with schizophrenia spectrum disorders (ICD-10 F20-29) and their family members, addressing a documented care gap in Germany where only 1–2% of patients receive outpatient psychotherapy, psychiatrist appointments occur roughly every two months for around 20 minutes, and more than 50% of patients relapse within two years.

The company's product suite centers on Kiso Mind, a CE-marked Class I medical device under EU MDR 2017/745 that delivers evidence-based cognitive behavioral therapy (CBT) and metacognitive training via structured video, audio, and interactive modules, combined with daily mood tracking, medication reminders, and crisis planning. A companion app, Kiso Care, supports relatives with coping strategies, local resource finding, and crisis guidance. Both apps were publicly launched in 2025 on iOS and Android. Clinical validation is in progress through the Charité-led CLIPS trial (led by PD Dr. Eric Hahn), and AI-driven personalization is in development under a dedicated AI engineer (Dr. Matthias Schultze-Kraft).

Kiso Health operates a freemium consumer model: Kiso Mind's basic tier is free, with an optional Plus subscription purchased via Apple Pay or Google Pay unlocking full modules, extended mood analysis, and daily tips. A secondary go-to-market path targets healthcare professionals through a dedicated 'Für Fachkreise' channel, and health insurance reimbursement (Kostenübernahme durch Krankenkassen) is in preparation. The company has been funded to date exclusively by non-dilutive German and European grants (EXIST Stipendium, European Social Fund, Profund Innovation, Science and Startups, Medical Innovations Incubator) and won the BMWK Gründungspreis 2023; no equity financing, revenue figures, or paying enterprise customers are disclosed.

Name

Kiso Health

Legal name

Kiso Health GmbH

Website

https://kisohealth.de

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Kiso Health is a Berlin-based digital therapeutics company spun out of Charité that builds the CE-marked Kiso Mind and Kiso Care mobile apps to deliver guideline-aligned CBT and mood/medication support to people with schizophrenia spectrum disorders and their families in Germany.

Ownership category

akta.pro rank

Product category

Digital Mental Health Therapeutics

NAICS

Outpatient Mental Health and Substance Abuse Centers (62142), Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Behavioral Health & Substance Use Remote Monitoring (HLACAFAD), Serious Mental Illness (SMI) Telepsychiatry & Care Coordination Platforms (HLALAEAH)

Keywords

• Digital therapeutics
• Mental health apps
• Psychosis treatment
• Cognitive behavioral therapy
• Medical mobile apps

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Freemium App – Basic Tier: Free version of Kiso Mind provides core therapeutic exercises (first section of each module), a 7-day mood check, crisis planning, and medication reminders. No cost to users; serves as acquisition and engagement layer.
2. Premium Subscription – Plus Version (in-app purchase): Plus version provides full access to all modules, extended mood-check analysis, and daily tips. Purchased via Apple Pay or Google Pay as a subscription. Revenue is usage-based/subscription recurring from end consumers. Cost coverage by health insurance (Krankenkassen) is in preparation.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Kiso Health develops and sells CE-marked Class I medical device (MDR 2017/745) mobile applications — Kiso Mind for individuals with schizophrenia spectrum disorders (ICD-10 F20-29) and Kiso Care for their family members. Kiso Mind delivers evidence-based cognitive behavioral therapy (CBT) exercises via structured pathways (video, audio, interactive), daily mood tracking, medication reminders, crisis planning, and clinician data-sharing, with a free base tier and an optional Plus subscription.

Product overview

Kiso Health offers a digital therapeutic ecosystem consisting of two complementary mobile applications: Kiso Mind for affected individuals with schizophrenia-spectrum disorders and Kiso Care for their relatives and family members. Kiso Mind provides evidence-based cognitive behavioral therapy exercises, mood tracking, medication reminders, and crisis planning through structured pathways. Both apps are available as free base versions, with Kiso Mind offering an optional Plus subscription for extended features. The products are CE-certified medical devices developed in collaboration with Charité Universitätsmedizin Berlin.

Differentiator

Problem solved

Functional benefit

Brands

• Kiso Mind: Therapeutic smartphone app for people with schizophrenia spectrum disorders (ICD-10 F20-29) providing cognitive behavioral therapy exercises, mood checks, medication reminders, and crisis planning
• Kiso Care

Products and services

• Kiso Mind A therapeutic smartphone application for individuals with schizophrenia spectrum disorders (ICD-10 F20-29) providing evidence-based cognitive behavioral therapy (CBT) exercises through structured pathways delivered via video, audio, and interactive modules. Includes daily mood checks (Stimmungs-Check), medication adherence reminders, crisis planning (Krisenplan), and emergency contact management. Designed for daily self-management and to bridge the gap between infrequent psychiatric appointments.
• Kiso Care A companion mobile application for family members, relatives, and friends of people with psychosis or schizophrenia. Supports the development of healthy coping strategies for supporting a loved one with psychosis, helps users find local resources such as clinics or psychotherapy, and provides guidance on what to do in a crisis. Developed by psychologists with input from affected family members.

Quantifiable outcome

• Approximately 1–2% of people with schizophrenia in Germany receive outpatient psychotherapy, illustrating a massive care gap that Kiso Mind addresses
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature7 records

Partnerships

One partnership is on record.

• Charité Universitätsmedizin BerlincoreStrategic or Co-development PartnerKiso Health is a spinout (Ausgründung) from Charité Universitätsmedizin Berlin. The co-founder and Chief Scientific Officer, Prof. Dr. Dr. Kerem Böge, leads the psychosis and schizophrenia research unit at Charité. The companies collaborate on clinical studies (CLIPS study led by PD Dr. Eric Hahn) and product development. The Charité study evaluates the efficacy of Kiso Mind for people with psychosis across a 12-week period.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Others

• Doccla: UK-based virtual ward and remote patient monitoring provider extending clinical care into the home. Comparable in the sense of providing continuous remote monitoring and clinician dashboards for chronic or serious conditions, although focused on physical rather than mental health.

Direct peers

• Selfapy: Berlin-based DTx company offering psychologist-led online courses and DiGA-listed programs for depression and other mental-health conditions. Comparable as a Germany-focused mental-health DTx with a similar therapist-supplemented digital therapy model and German reimbursement pathway.
• HelloBetter: Hamburg-based digital therapeutics company (formerly GET.ON) with multiple DiGA-listed mental-health programs (depression, stress, insomnia). Comparable as a German DTx peer targeting similar clinicians and Krankenkassen reimbursement, although operating in adjacent indications rather than psychosis.
• Mindable Health: A Berlin-based digital therapeutics startup offering a CE-marked, DiGA-listed app for panic disorder and agoraphobia. Closely comparable to Kiso Health in business model (CE-marked mental-health DTx, German-focused, freemium + prescription pathway, B2B2C motion via clinicians and Krankenkassen).

Emerging players

• Akili Interactive: US-based digital therapeutic company with FDA-cleared, prescription-grade cognitive therapy products (e.g., for ADHD and cognitive dysfunction). Comparable as a regulated, prescription-oriented DTx in adjacent cognitive/behavioral indications, though operating in the US regulatory environment rather than EU MDR.
• Compass Pathways: Mental-health company developing psilocybin therapy for treatment-resistant depression, with clinical-trial-driven evidence generation. Comparable as a serious-mental-illness therapeutics company pursuing rigorous clinical validation, although focused on pharmacological rather than digital intervention.
• Cerebral: US-based telehealth and medication-management platform for anxiety, depression, and insomnia. Comparable as a digital channel for serious mental-health conditions combining clinician oversight with consumer subscription, though operating a much broader service rather than a focused CBT DTx.
• Big Health: US/UK digital therapeutics company offering Sleepio (insomnia) and Daylight (anxiety), with growing European payer partnerships. Comparable as a clinically validated, evidence-based mental-health DTx pursuing payer and clinician adoption, though focused on anxiety/sleep rather than psychosis.

Broad incumbents

• Oviva: Swiss/German digital health company providing app-based guidance for diet-related and chronic conditions, with established German Krankenkassen reimbursement. Comparable as a Europe-based, regulatorily cleared digital health company pursuing DiGA-style reimbursement and clinician-led adoption.
• GAIA AG: Hamburg-based pioneer of digital therapeutics with products like deprexis and velibra covering depression, anxiety, and insomnia. Historically the most direct German DTx comparator, though the company has faced insolvency; relevant as the precedent Kiso Health most closely resembles in model, even though its operational status is constrained.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kisohealth
• Instagraminstagram.com/kisohealth

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kiso Health